Skip to content
2000
Volume 3, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format pdf download PDF
side by side viewer icon HTML

Abstract

Cancer is a complex disorder characterized by the unregulated proliferation of cells that have the potential to invade other regions of the body. It stems from genetic alterations in various cell types, resulting in tumor formation. These growths are classified as benign (noncancerous) or malignant (cancerous). Unlike benign tumors, which typically remain localized, malignant tumors can spread, infiltrate nearby tissues, and establish secondary growth in organs far from the original site. The treatment approach depends on the specific type and progression of cancer, encompassing options such as surgical intervention, radiation-based therapies, drug-based treatments, immune system-boosting techniques, and therapies targeting particular cellular mechanisms. Skin cancer is a common occurrence among various cancer types, especially in populations with lighter skin tones. Skin cancer is a prevalent form of cancer, particularly in the Caucasian population. The most common skin cancers are basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. BCCs, which arise from the basal layer of the epidermis, are often treated with surgery, topical therapies, or cryotherapy depending on their risk and location. Mohs micrographic surgery is effective for high-risk or recurrent BCCs, whereas topical treatments such as 5-fluorouracil and imiquimod are used for superficial BCCs. Early diagnosis through biopsy and various imaging techniques is crucial for effective management. Advances in treatment, including targeted therapies and improved surgical techniques, continue to enhance patient outcomes and reduce recurrence rates. Understanding these diverse aspects of cancer and skin cancer will help devise effective treatment strategies and improve patient prognosis.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X350515241208061724
2024-12-11
2025-09-25

  • From This Site

    /content/journals/cis/10.2174/012210299X350515241208061724
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/3/1/CIS-3-E2210299X350515.html?itemId=/content/journals/cis/10.2174/012210299X350515241208061724&mimeType=html&fmt=ahah

References

  1. What Is Cancer? - NCI2023Avaialable from: https://www.cancer.gov/about-cancer/understanding/what-is-cancer (May 7, 2023).
  2. Cancer2023Avaialable from: https://www.who.int/news-room/fact-sheets/detail/cancer (May 7, 2023).
  3. 2023Cancer Staging Avaialable from: https://www.cancer.gov/about-cancer/diagnosis-staging/staging (May 7, 2023).
  4. Treatment by Cancer Type 2023Avaialable from: https://www.nccn.org/guidelines/category_1
  5. PadalaS.A. BarsoukA. ThandraK.C. SaginalaK. MohammedA. VakitiA. Epidemiology of renal cell carcinoma. World J Oncol.2020113798710.14740/wjon1279.
     [Google Scholar]
  6. GrünewaldT.G.P. AlonsoM. AvnetS. BanitoA. BurdachS. Cidre-AranazF. Di PompoG. DistelM. Dorado-GarciaH. Garcia-CastroJ. González-GonzálezL. GrigoriadisA.E. KasanM. KoelscheC. KrumbholzM. LecandaF. LemmaS. LongoD.L. Madrigal-EsquivelC. Morales-MolinaÁ. MusaJ. OhmuraS. OryB. Pereira-SilvaM. PerutF. RodriguezR. SeelingC. Al ShaailiN. ShaabaniS. ShiavoneK. SinhaS. TomazouE.M. TrautmannM. VelaM. Versleijen-JonkersY.M.H. VisgaussJ. ZalacainM. SchoberS.J. LissatA. EnglishW.R. BaldiniN. HeymannD. Sarcoma treatment in the era of molecular medicine.EMBO Mol. Med.20201211e1113110.15252/emmm.20191113133047515
     [Google Scholar]
  7. DevineS.M. LarsonR.A. Acute leukemia in adults: Recent developments in diagnosis and treatment.CA Cancer J. Clin.199444632635210.3322/canjclin.44.6.3267953914
     [Google Scholar]
  8. BrigleK. RogersB. Pathobiology and diagnosis of multiple myeloma.Semin. Oncol. Nurs.201733322523610.1016/j.soncn.2017.05.01228688533
     [Google Scholar]
  9. Carcinoma: Types, treatment and what it is?2023Avaialable from: https://my.clevelandclinic.org/health/diseases/23180-carcinoma
  10. What is Carcinoma? Metastatic, in situ and invasiveAvaialable from: https://www.cancercenter.com/carcinoma
  11. Skin cancer statistics | World Cancer Research Fund International 2023Avaialable from:https://www.wcrf.org/cancer-trends/skin-cancer-statistics/ (October 30, 2023).
  12. CullenJ.K. SimmonsJ.L. ParsonsP.G. BoyleG.M. Topical treatments for skin cancer.Adv Drug Deliv Rev.2020153546410.1016/j.addr.2019.11.002.
     [Google Scholar]
  13. BonillaX. ParmentierL. KingB. BezrukovF. KayaG. ZoeteV. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.Nat Genet.201648439810.1038/ng.3525
     [Google Scholar]
  14. PandeyaN. OlsenC.M. WhitemanD.C. The incidence and multiplicity rates of keratinocyte cancers in Australia.Med. J. Aust.2017207833934310.5694/mja17.0028429020905
     [Google Scholar]
  15. GreenA.C. OlsenC.M. Cutaneous squamous cell carcinoma: An epidemiological review.Br. J. Dermatol.2017177237310.1111/bjd.1532428211039
     [Google Scholar]
  16. Scopus preview - Scopus - Welcome to Scopus.2023Avaialable from: https://www.scopus.com/home.uri
  17. WasehS. LeeJ.B. Advances in melanoma: Epidemiology, diagnosis, and prognosis.Front. Med. (Lausanne)202310126847910.3389/fmed.2023.126847938076247
     [Google Scholar]
  18. SwetterS.M. TsaoH. BichakjianC.K. Curiel-LewandrowskiC. ElderD.E. GershenwaldJ.E. GuildV. Grant-KelsJ.M. HalpernA.C. JohnsonT.M. SoberA.J. ThompsonJ.A. WiscoO.J. WyattS. HuS. LaminaT. Guidelines of care for the management of primary cutaneous melanoma.J. Am. Acad. Dermatol.201980120825010.1016/j.jaad.2018.08.05530392755
     [Google Scholar]
  19. BichakjianC.K. HalpernA.C. JohnsonT.M. Foote HoodA. GrichnikJ.M. SwetterS.M. TsaoH. BarbosaV.H. ChuangT.Y. DuvicM. HoV.C. SoberA.J. BeutnerK.R. BhushanR. Smith BegolkaW. American Academy of Dermatology Guidelines of care for the management of primary cutaneous melanoma.J. Am. Acad. Dermatol.20116551032104710.1016/j.jaad.2011.04.03121868127
     [Google Scholar]
  20. KimD.P. KusK.J.B. RuizE. Basal cell carcinoma review.Hematol Oncol Clin North Am. 2019331132410.1016/j.hoc.2018.09.004
     [Google Scholar]
  21. MasonRS ReichrathJ Sunlight vitamin D and skin cancer. Anticancer Agents Med Chem.20131318323094924
     [Google Scholar]
  22. AllenH. Skin cancer. Oxford Handbook of Cancer Nursing.Oxford University Press201910.1093/med/9780198701101.003.0034
     [Google Scholar]
  23. LinaresM.A. ZakariaA. NizranP. Skin Cancer.Prim. Care201542464565910.1016/j.pop.2015.07.00626612377
     [Google Scholar]
  24. AhmedB. QadirM.I. GhafoorS. Malignant melanoma: Skin cancer—diagnosis, prevention, and treatment.Crit. Rev. Eukaryot. Gene Expr.202030429129710.1615/CritRevEukaryotGeneExpr.202002845432894659
     [Google Scholar]
  25. DildarM. AkramS. IrfanM. KhanH.U. RamzanM. MahmoodA.R. AlsaiariS.A. SaeedA.H.M. AlraddadiM.O. MahnashiM.H. Skin cancer detection: A review using deep learning techniques.Int. J. Environ. Res. Public Health20211810547910.3390/ijerph1810547934065430
     [Google Scholar]
  26. PerisK. FargnoliM.C. GarbeC. KaufmannR. BastholtL. SeguinN.B. BatailleV. MarmolV. DummerR. HarwoodC.A. HauschildA. HöllerC. HaedersdalM. MalvehyJ. MiddletonM.R. MortonC.A. NagoreE. StratigosA.J. SzeimiesR.M. TagliaferriL. TrakatelliM. ZalaudekI. EggermontA. GrobJ.J. European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines.Eur. J. Cancer2019118103410.1016/j.ejca.2019.06.00331288208
     [Google Scholar]
  27. Basset-SeguinN. HermsF. Update on the management of basal cell carcinoma.Acta Derm Venereol. 202010011adv0014010.2340/00015555‑3495
     [Google Scholar]
  28. DorrellD.N. StrowdL.C. Skin cancer detection technology.Dermatol. Clin.201937452753610.1016/j.det.2019.05.01031466592
     [Google Scholar]
  29. GreenwoodJ.D. MerryS.P. BoswellC.L. Skin biopsy techniques.Prim. Care202249112210.1016/j.pop.2021.10.00135125151
     [Google Scholar]
  30. BauerJ. BüttnerP. LutherH. WieckerT.S. MöhrleM. GarbeC. Blue light phototherapy of neonatal jaundice does not increase the risk for melanocytic nevus development.Arch. Dermatol.2004140449349410.1001/archderm.140.4.49315096388
     [Google Scholar]
  31. HassH.G. SchmidtA. NehlsO. KaiserS. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC) – Potential implications for clinical management and treatment decisions.Oral Oncol.2008441788510.1016/j.oraloncology.2006.12.01317350326
     [Google Scholar]
  32. LeonR. Martinez-VegaB. FabeloH. OrtegaS. MelianV. CastañoI. CarreteroG. AlmeidaP. GarciaA. QuevedoE. HernandezJ.A. ClavoB. M CallicoG. Non-invasive skin cancer diagnosis using hyperspectral imaging for in-situ clinical support.J. Clin. Med.202096166210.3390/jcm906166232492848
     [Google Scholar]
  33. Christensen-JeffriesK. CoutureO. DaytonP.A. EldarY.C. HynynenK. KiesslingF. O’ReillyM. PintonG.F. SchmitzG. TangM.X. TanterM. van SlounR.J.G. Super-resolution Ultrasound Imaging.Ultrasound Med. Biol.202046486589110.1016/j.ultrasmedbio.2019.11.01331973952
     [Google Scholar]
  34. DanielH. MaglioG. ElianaM. LeoniJ. Cyclooxygenase-2 overexpression in non-melanoma skin cancer: Molecular pathways involved as targets for prevention and treatment.Skin Cancers - Risk Factors, Prevention and TherapyINTECH Open Access Publisher201117519610.5772/26355
     [Google Scholar]
  35. HuangH.Y. HsiaoY.P. KarmakarR. MukundanA. ChaudharyP. HsiehS.C. WangH.C. A review of recent advances in computer-aided detection methods using hyperspectral imaging engineering to detect skin cancer.Cancers20231523563410.3390/cancers1523563438067338
     [Google Scholar]
  36. GoyalR. HusainS. WilsonK. ChopraH. PahwaR. LoganathanM. Recent advancements in skin cancer treatment: A critical review.Explor Med.20234578210.37349/emed.2023.00178
     [Google Scholar]
  37. DesaiV.M. KumbharP. KadamA.Y. SwarupJ. PriyaS. JainA. SinghviG. Exploring the therapeutic modalities of targeted treatment approach for skin carcinoma: Cutting-edge strategies and key insights.Expert Opin. Drug Deliv.20242181213123310.1080/17425247.2024.239279939136542
     [Google Scholar]
  38. Smak GregoorA.M. SangersT.E. BakkerL.J. HollesteinL. Uyl - de GrootC.A. NijstenT. WakkeeM. An artificial intelligence based app for skin cancer detection evaluated in a population based setting.NPJ Digit. Med.2023619010.1038/s41746‑023‑00831‑w37210466
     [Google Scholar]
  39. AbobakerM. GovenderM. ChoonaraY.E. Non-surgical synergistic interventions for the treatment of skin cancer.Curr. Pharm. Des.20243010.2174/011381612829826424053006103938910485
     [Google Scholar]
  40. QuaziS.J. AslamN. SaleemH. RahmanJ. KhanS. Surgical margin of excision in basal cell carcinoma: A systematic review of literature.Cureus2020127e921110.7759/cureus.921132821563
     [Google Scholar]
  41. van LooE. MosterdK. KrekelsG.A.M. RoozeboomM.H. OstertagJ.U. DirksenC.D. SteijlenP.M. NeumannH.A.M. NelemansP.J. Kelleners-SmeetsN.W.J. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10year follow-up.Eur. J. Cancer201450173011302010.1016/j.ejca.2014.08.01825262378
     [Google Scholar]
  42. TalbotS. HitchcockB. Incomplete primary excision of cutaneous basal and squamous cell carcinomas in the Bay of Plenty.N. Z. Med. J.20041171192U84815107870
     [Google Scholar]
  43. MasudD. MoustakiM. StaruchR. DheansaB. Basal cell carcinomata: Risk factors for incomplete excision and results of re-excision.J. Plast. Reconstr. Aesthet. Surg.201669565265610.1016/j.bjps.2015.12.02426948998
     [Google Scholar]
  44. SilvermanM.K. KopfA.W. GrinC.M. BartR.S. LevensteinM.J. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation.J. Dermatol. Surg. Oncol.199117972072610.1111/j.1524‑4725.1991.tb03425.x1820764
     [Google Scholar]
  45. GoldmanG. The current status of curettage and electrodesiccation.Dermatol. Clin.2002203569578, ix10.1016/S0733‑8635(02)00022‑012170889
     [Google Scholar]
  46. ChampeauM. VignoudS. MortierL. MordonS. Photodynamic therapy for skin cancer: How to enhance drug penetration?J. Photochem. Photobiol. B201919711154410.1016/j.jphotobiol.2019.11154431295716
     [Google Scholar]
  47. StollA. van OepenA. FriebeM. Intraoperative delivery of cell-killing boost radiation: A review of current and future methods.Minim. Invasive Ther. Allied Technol.201625417618710.3109/13645706.2016.117356327161210
     [Google Scholar]
  48. TomM.C. JoshiN. ViciniF. ChangA.J. HongT.S. ShowalterT.N. ChaoS.T. WoldenS. WuA.J. MartinD. HusainZ. BadiyanS.N. KolarM. SherertzT. MourtadaF. CohenG.N. ShahC. The American Brachytherapy Society consensus statement on intraoperative radiation therapy.Brachytherapy201918324225710.1016/j.brachy.2019.01.01531084904
     [Google Scholar]
  49. MortonC.A. DominicusR. RadnyP. DirschkaT. HauschildA. ReinholdU. AschoffR. UlrichM. KeohaneS. Ekanayake-BohligS. IbbotsonS. OstendorfR. BerkingC. GröneD. SchulzeH.J. OckenfelsH.M. JasnochV. KurzenH. SebastianM. StegeH. StaubachP. GuptaG. HübingerF. ZiabrevaI. SchmitzB. GertzmannA. LübbertH. SzeimiesR.M. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.Br. J. Dermatol.2018179230931910.1111/bjd.1644129432644
     [Google Scholar]
  50. JansenM.H.E. MosterdK. AritsA.H.M.M. RoozeboomM.H. SommerA. EssersB.A.B. van PeltH.P.A. QuaedvliegP.J.F. SteijlenP.M. NelemansP.J. Kelleners-SmeetsN.W.J. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma.J. Invest. Dermatol.2018138352753310.1016/j.jid.2017.09.03329045820
     [Google Scholar]
  51. GutzmerR. SolomonJ.A. Hedgehog pathway inhibition for the treatment of basal cell carcinoma.Target. Oncol.201914325326710.1007/s11523‑019‑00648‑231243642
     [Google Scholar]
  52. PakE. SegalR.A. Hedgehog signal transduction: Key players, oncogenic drivers, and cancer therapy.Dev. Cell201638433334410.1016/j.devcel.2016.07.02627554855
     [Google Scholar]
  53. VillaniA. PotestioL. FabbrociniG. ScalvenziM. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma.Adv Ther.2022 391164117810.1007/s12325‑022‑02044‑1.
     [Google Scholar]
  54. WilliamsH.C. Bath-HextallF. OzolinsM. ArmstrongS.J. ColverG.B. PerkinsW. MillerP.S.J. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-Year results of the SINS randomized controlled trial.J. Invest. Dermatol.2017137361461910.1016/j.jid.2016.10.01927932240
     [Google Scholar]
  55. ANNEX I: Summary of product characteristics.2024Avaialable from: https://ec.europa.eu/health/documents/community-register/2021/20210223151110/anx_151110_en.pdf
  56. KaatzM. MohrP. LivingstoneE. WeichenthalM. KreuterA. PföhlerC. LeiterU. UlrichJ. UtikalJ.S. GutzmerR. HerbstR. SchadendorfD. Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions: Non-interventional cohort study JONAS.Acta Derm. Venereol.2022102adv0069510.2340/actadv.v102.29335199180
     [Google Scholar]
  57. VillaniA. FabbrociniG. ScalvenziM. Sonidegib-induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt.Dermatol. Ther.2022357e1553110.1111/dth.15531
     [Google Scholar]
  58. RubattoM. SciamarrelliN. BorrielloS. PalaV. MastorinoL. TonellaL. RiberoS. QuaglinoP. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.Front. Med. (Lausanne)2023995928910.3389/fmed.2022.95928936844955
     [Google Scholar]
  59. DachaniS.R. KaleemM. MujtabaM.A. MahajanN. AliS.A. AlmutairyA.F. MahmoodD. AnwerM.K. AliM.D. KumarS. A comprehensive review of various therapeutic strategies for the management of skin cancer.ACS Omega202499100301004810.1021/acsomega.3c0978038463249
     [Google Scholar]
  60. SaeedW. ShahbazE. MaqsoodQ. AliS.W. MahnoorM. Cutaneous oncology: Strategies for melanoma prevention, diagnosis, and therapy.Cancer Contr.2024311073274824127497810.1177/1073274824127497839133519
     [Google Scholar]
  61. BhadouriaN. AlamA. KaurA. Unraveling skin carcinoma: A comprehensive examination of diagnosis, treatment strategies, and emerging therapeutic avenues in skin cancer management.Pharm. Nanotechnol.20241211610.2174/012211738528216324022007225138468531
     [Google Scholar]
  62. ZengL. GowdaB.H.J. AhmedM.G. AbourehabM.A.S. ChenZ.S. ZhangC. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer.20232211010.1186/s12943‑022‑01708‑4
     [Google Scholar]
  63. SolS. BonciminoF. TodorovaK. WaszynS.E. MandinovaA. Therapeutic approaches for non-melanoma skin cancer: Standard of Care and Emerging Modalities.Int. J. Mol. Sci.20242513705610.3390/ijms2513705639000164
     [Google Scholar]
  64. WilkenR. CriscitoM. PavlickA.C. StevensonM.L. CarucciJ.A. Current research in melanoma and aggressive nonmelanoma skin cancer.Facial Plast. Surg.202036220021010.1055/s‑0040‑170911832413929
     [Google Scholar]
  65. MaV.T. HaringC.T. WarrierG. SwiecickiP.L. Targeted therapy and traditional chemotherapy in melanoma and cutaneous squamous cell carcinoma.Facial Plast. Surg.202036218619310.1055/s‑0040‑170912632413927
     [Google Scholar]
  66. ChenY. LuY. LeeR.J. XiangG. Nano encapsulated curcumin: And its potential for biomedical applications.Int. J. Nanomedicine2020153099312010.2147/IJN.S21032032431504
     [Google Scholar]
  67. DeleanuM. TomaL. SandaG.M. BarbălatăT. NiculescuL.Ş. SimaA.V. DeleanuC. SăcărescuL. SuciuA. AlexandruG. CrişanI. PopescuM. StancuC.S. Formulation of phytosomes with extracts of ginger rhizomes and rosehips with improved bioavailability, antioxidant and anti-inflammatory effects in vivo.Pharmaceutics2023154106610.3390/pharmaceutics1504106637111552
     [Google Scholar]
  68. Noor-E-Tabassum. Das R. Lami M.S. Chakraborty A.J. Mitra A.S. Tallei T.E. Idroes R. Ginkgo biloba: A treasure of functional phytochemicals with multimedicinal application.Evid Based Complement Alternat Med20222022828881810.1155/2022/8288818.
     [Google Scholar]
  69. GilaniS.A. HaqIahtisham-Ul M.Imran IAhmad T.AGondal. A.Akram. Anticancer perspectives of sanguinarine: A review.Curr. Bioact. Compd.20221892229
     [Google Scholar]
  70. ThitimutaS. PithayanukulP. NithitanakoolS. BavovadaR. LeanpolchareanchaiJ. SaparpakornP. Camellia sinensis L. extract and its potential beneficial effects in antioxidant, anti-inflammatory, anti-hepatotoxic, and anti-tyrosinase activities.Molecules201722340110.3390/molecules2203040128273866
     [Google Scholar]
  71. SinghN. YadavS.S. RaoA.S. NandalA. KumarS. GanaieS.A. NarasihmanB. Review on anticancerous therapeutic potential of Withania somnifera (L.). Dunal.J. Ethnopharmacol.202127011370410.1016/j.jep.2020.11370433359918
     [Google Scholar]
  72. ParkK.K. ChunK.S. LeeJ.M. LeeS.S. SurhY.J. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice.Cancer Lett.1998129213914410.1016/S0304‑3835(98)00081‑09719454
     [Google Scholar]
  73. LipsonE.J. LiloM.T. OgurtsovaA. EsandrioJ. XuH. BrothersP. SchollenbergerM. SharfmanW.H. TaubeJ.M. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.J. Immunother. Cancer2017512310.1186/s40425‑017‑0228‑328344809
     [Google Scholar]
  74. LebasE. MarchalN. RoriveA. NikkelsA.F. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: Safety, efficacy, and position in therapy panel.Expert Rev. Anticancer Ther.202121435536310.1080/14737140.2021.187656733554680
     [Google Scholar]
  75. VillaniA. Ocampo-GarzaS.S. PotestioL. FabbrociniG. Ocampo-CandianiJ. Ocampo-GarzaJ. ScalvenziM. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.Expert Opin. Drug Saf.2022211212910.1080/14740338.2022.199381934644510
     [Google Scholar]
  76. HughesB.G.M. Munoz-CouseloE. MortierL. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial. Ann Oncol.20213210127610.1016/j.annonc.2021.07.008
     [Google Scholar]
  77. WolchokJ.D. KlugerH. CallahanM.K. PostowM.A. RizviN.A. LesokhinA.M. SegalN.H. AriyanC.E. GordonR.A. ReedK. BurkeM.M. CaldwellA. KronenbergS.A. AgunwambaB.U. ZhangX. LowyI. InzunzaH.D. FeelyW. HorakC.E. HongQ. KormanA.J. WiggintonJ.M. GuptaA. SznolM. Nivolumab plus ipilimumab in advanced melanoma.N. Engl. J. Med.2013369212213310.1056/NEJMoa130236923724867
     [Google Scholar]
  78. PostowM.A. ChesneyJ. PavlickA.C. RobertC. GrossmannK. McDermottD. LinetteG.P. MeyerN. GiguereJ.K. AgarwalaS.S. ShaheenM. ErnstoffM.S. MinorD. SalamaA.K. TaylorM. OttP.A. RollinL.M. HorakC. GagnierP. WolchokJ.D. HodiF.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N. Engl. J. Med.2015372212006201710.1056/NEJMoa141442825891304
     [Google Scholar]
  79. MarconciniR. FavaP. NuzzoA. ManacordaS. FerrariM. De RosaF. De TursiM. TandaE.T. ConsoliF. MinisiniA. PimpinelliN. MorgeseF. BersanelliM. TucciM. SaponaraM. ParisiA. OcelliM. BazzurriS. MassaroG. MorgantiR. CiardettiI. StanganelliI. Comparison between first line target therapy and immunotherapy in different prognostic categories of braf mutant metastatic melanoma patients: An italian melanoma intergroup study.Front. Oncol.20221291799910.3389/fonc.2022.91799936046043
     [Google Scholar]
  80. TeoJ.J. NossierR. ChauhanA. TanT.Z. NgaV.D.W. AB050. Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: A systematic review & network meta-analysis.Chin Clin Oncol 202413Suppl. 1AB050AB050
     [Google Scholar]
  81. MerolaJ.P. OcenJ. KumarS. PowellJ. HayhurstC. Survival in melanoma brain metastases in the era of novel systemic therapies.Neurooncol. Adv.202021vdaa14410.1093/noajnl/vdaa14433392503
     [Google Scholar]
  82. BadamiS. UpadhayaS. VelagapudiR.K. MikkilineniP. KunworR. Al HadidiS. BachuwaG. Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors.J. Oncol.20182018111310.1155/2018/627987130112001
     [Google Scholar]
  83. MahdiabadiS. MomtazmaneshS. KarimiA. RezaeiN. Immune checkpoint inhibitors in advanced cutaneous melanoma: A systematic review and meta-analysis of efficacy and review of characteristics.Expert Rev. Anticancer Ther.202323121281129310.1080/14737140.2023.227850937908134
     [Google Scholar]
  84. Al-SuwayehSA TahaEI Al-QahtaniFM AhmedMO BadranMM Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer.Scientific World. J.2014201412749510.1155/2014/127495
     [Google Scholar]
  85. GuimarãesK.L. RéM.I. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the Second Generation (NLC)Nanocosmetics and NanomedicinesSpringer201110112210.1007/978‑3‑642‑19792‑5_5
     [Google Scholar]
  86. TiwariN. Osorio-BlancoE.R. SonzogniA. Esporrín-UbietoD. WangH. CalderónM. Nanocarriers for skin applications: Where do we stand?Angew. Chem. Int. Ed.2022613e20210796010.1002/anie.20210796034487599
     [Google Scholar]
  87. NikolićI. SimićM. PantelićI. StojanovićG. Antić StankovićJ. MarkovićB. SavićS. Chemical vs. physical methods to improve dermal drug delivery: A case study with nanoemulsions and iontophoresis.Pharmaceutics2022146114410.3390/pharmaceutics1406114435745717
     [Google Scholar]
  88. SinghB.N. SinghR.B. SinghJ. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum.Int. J. Pharm.200529819810710.1016/j.ijpharm.2005.04.00415913928
     [Google Scholar]
  89. HeraiH. GratieriT. ThomazineJ. BentleyM. LopezR. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations.Int. J. Pharm.20073291-2889310.1016/j.ijpharm.2006.08.02117027205
     [Google Scholar]
  90. SimonettiL.D.D. GelfusoG.M. BarbosaJ.C.R. LopezR.F.V. Assessment of the percutaneous penetration of cisplatin: The effect of monoolein and the drug skin penetration pathway.Eur. J. Pharm. Biopharm.2009731909410.1016/j.ejpb.2009.04.01619442727
     [Google Scholar]
  91. ManconiM. SinicoC. CaddeoC. VilaA.O. ValentiD. FaddaA.M. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin.Int. J. Pharm.20114121-2374610.1016/j.ijpharm.2011.03.06821530626
     [Google Scholar]
  92. StelutiR. DerosaF. CollettJ. TedescoA. BentleyM. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin.Eur. J. Pharm. Biopharm.200560343944410.1016/j.ejpb.2005.01.01115996585
     [Google Scholar]
  93. BugajA. JuzenieneA. JuzenasP. IaniV. MaL.W. MoanJ. The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid.J. Photochem. Photobiol. B2006832949710.1016/j.jphotobiol.2005.12.00316442808
     [Google Scholar]
  94. BugajA. IaniV. JuzenieneA. JuzenasP. MaL.W. MoanJ. The effect of dimethylsulfoxide, 1-[2-(decylthio)ethyl]azacyclopentan-2-one and Labrafac®CC on porphyrin formation in normal mouse skin during topical application of methyl 5-aminolevulinate: A fluorescence and extraction study.Photodiagn. Photodyn. Ther.200631273310.1016/S1572‑1000(05)00109‑225049025
     [Google Scholar]
/content/journals/cis/10.2174/012210299X350515241208061724
Loading
Review Understanding of the Many Facets of Cancer and the Management of Skin Cancer
Curr. Indian Sci. 3, e2210299X350515 (2025); https://doi.org/10.2174/012210299X350515241208061724
/content/journals/cis/10.2174/012210299X350515241208061724
/content/journals/cis/10.2174/012210299X350515241208061724
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cancer; Phytochemicals; Skin cancer; Strategies; Topical therapies; Treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test